Novel, selective mechanism-based inhibitors of the herpes proteases

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 20, 1996, Pages 2467-2472

  Pinto, Ivan L ^a   West, Andrew ^a   Debouck, Christine M ^a   DiLella, Anthony G ^a   Gorniak, Joselina G ^a   O'Donnell, Kevin C ^a   O'Shannessy, Daniel J ^a   Patel, Arunbai ^a   Jarvest, Richard L ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CHYMOTRYPSIN; ELASTASE; IMIDAZOLE DERIVATIVE; OXAZOLE DERIVATIVE; PROTEINASE; PROTEINASE INHIBITOR; SPIRO COMPOUND; TRYPSIN;

ARTICLE; CYTOMEGALOVIRUS; DRUG DESIGN; ENZYME BINDING; ENZYME INHIBITION; HERPES VIRUS;

CYTOMEGALOVIRUS; HERPES; HERPESVIRIDAE; HUMAN HERPESVIRUS 2;

EID: 0030598180     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-894X(96)00456-8     Document Type: Article

References (17)

1. 1. Goodgame, R. W., Ann. Intern. Med. 1993, 119, 924.
2. 2. Liu, F.; Roizman, B., J. Virol. 1991, 65, 5149.
3. 3. Welsh, A. R.; Woods, A. S.; McNally, L. M.; Cotter, R. J.; Gibson, W., Proc. Natl. Acad. Sci. USA, 1991, 88, 10792
4. 4. Sardana, C. L.; Wolfgang, J. A.; Veloski, C. A.; Long, W. J.; LeGrow, K.; Wolinski, B.; Emini, E. A.; LaFemina, R. L., J. Biol. Chem. 1994, 269, 14337.
5. 5. Jones, T. R.; Sun, L.; Bebernitz, G. A.; Muzithras, V. P.; Kim, H-J.; Johnson, S. M.; Baum, E. Z., J. Virol. 1994, 68, 2742.
6. 6. Dilanni, C. L.; Stevens, J. T.; Bolger, M.; O'Boyle, D. R.; Weinheimer, S. P.; Colonno, R. J., J. Biol Chem. 1994, 269, 12672.
7. 16,17 or HCMV protease catalytic domain for 15 min in 25 uL buffer (50 mM sodium phosphate, 150 mM sodium chloride, 0.001mM EDTA, 0.01% PEG 3400; pH 8.0) then adding 250 μM R-site 14-mer peptide substrate, Ac-HTYLQASEKFKMWG and incubating at 27°C for 60 mins. The reaction was quenched with 40 μL 5% trifluoroacetic acid solution and the extent of proteolysis examined by quantifying the amounts of the substrate peptide and of the N-terminal and C-terminal cleavage fragments by HPLC analysis. The percentage cleavage was calculated and expressed as a fraction of the value obtained for an uninhibited control sample. Compounds 16-19 were assayed in a quenched fluorescence peptidolytic assay (A. Patel, unpublished results).
8. 8. Mass spectra analysis was carried out by reverse phase HPLC electrospray on a Finnigan TSQ700 and post source decay MS/MS on a Micromass TOF Spec E.
9. 9. Cativiela, C.; Diaz de Villegas, M. D.; Mayoral, J. A.; Melendez, E., J. Org. Chem. 1984, 49, 1436.
10. 10. Pages, R. A.; Burger, A., J. Org. Chem. 1967,10, 435.
11. 11. All compounds are racemic and gave satisfactory spectroscopic and analytical date.
12. 12. Badr, M. Z.; El-Sherief, H. A. H.; Tadros, M. E., Bull. Chem. Soc. Jpn. 1982, 55, 2267.
13. 3):-δ 3.5 (s, 3H); 7.3 (s, 1H); 7.5 (m, 6H); 8.2 (dd, J = 7 & 2 Hz, 2H); 8.25 (dd, J = 7 & 2 Hz, 2H).
14. 14. Groutas, W. C.; Brubaker, M. J.; Stanga, M. A.; Castrisos, J. C.; Crowley, J. P.; Schatz, E. J., J. Med. Chem. 1989, 32, 1607.
15. 15. Groutas, W. C.; Stanga, M. A.; Brubaker, M. J., J. Am. Chem. Soc. 1989, 111, 1931.
16. 16. Steffy, K. R.; Scheon, S.; Chen, C-M., J. Gen. Virol. 1995, 76, 1069.
17. 17. DiLella, A. G.; Debouck, C. M., WO Patent Application 95/06055 ( to SmithKline Beecham), 1995.